Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thavarak Ouk

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Biomolecules|June 27, 2024
Endothelial Dysfunction and Pre-Existing Cognitive Disorders in Stroke PatientsAnne-Marie Mendyk-Bordet, Thavarak Ouk, Anne Muhr-Tailleux, et al.
Therapie|May 17, 2021
Overview of clinical trials vigilance units in French institutional sponsors - A study from the REVISE working groupNadine Petitpain, Pascale Olivier, Sabrina Crépin, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|January 9, 2014
Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemiaThavarak Ouk, Sophie Gautier, Maud Pétrault, et al.
Clinical Trials (London, England)|February 7, 2020
Compliance of French academic clinical trials with the Clinical Trial Facilitation and Coordination Group recommendations on contraception and pregnancy testing requirementsSabrina Crepin, Anne Chiffoleau, Marylaure Gavard, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2013
Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trialDavid Devos, Caroline Moreau, David Maltête, et al.
Nature Medicine|January 8, 2025
Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related complications: a phase 1/2 randomized-controlled trialCaroline Moreau, Pascal Odou, Julien Labreuche, et al.
Neurology|November 6, 2016
Proportion of single-chain recombinant tissue plasminogen activator and outcome after strokeDidier Leys, Yannick Hommet, Clémence Jacquet, et al.
The New England Journal of Medicine|November 30, 2022
Trial of Deferiprone in Parkinson's DiseaseDavid Devos, Julien Labreuche, Olivier Rascol, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Biomolecules|June 27, 2024
Endothelial Dysfunction and Pre-Existing Cognitive Disorders in Stroke PatientsAnne-Marie Mendyk-Bordet, Thavarak Ouk, Anne Muhr-Tailleux, et al.
Therapie|May 17, 2021
Overview of clinical trials vigilance units in French institutional sponsors - A study from the REVISE working groupNadine Petitpain, Pascale Olivier, Sabrina Crépin, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|January 9, 2014
Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemiaThavarak Ouk, Sophie Gautier, Maud Pétrault, et al.
Clinical Trials (London, England)|February 7, 2020
Compliance of French academic clinical trials with the Clinical Trial Facilitation and Coordination Group recommendations on contraception and pregnancy testing requirementsSabrina Crepin, Anne Chiffoleau, Marylaure Gavard, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2013
Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trialDavid Devos, Caroline Moreau, David Maltête, et al.
Nature Medicine|January 8, 2025
Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related complications: a phase 1/2 randomized-controlled trialCaroline Moreau, Pascal Odou, Julien Labreuche, et al.
Neurology|November 6, 2016
Proportion of single-chain recombinant tissue plasminogen activator and outcome after strokeDidier Leys, Yannick Hommet, Clémence Jacquet, et al.
The New England Journal of Medicine|November 30, 2022
Trial of Deferiprone in Parkinson's DiseaseDavid Devos, Julien Labreuche, Olivier Rascol, et al.
Pageof 3